Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malignant Glioma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H1 2015', provides an overview of the Malignant Glioma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Glioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Malignant Glioma Overview 8 Therapeutics Development 9 Pipeline Products for Malignant Glioma - Overview 9 Pipeline Products for Malignant Glioma - Comparative Analysis 10 Malignant Glioma - Therapeutics under Development by Companies 11 Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 13 Malignant Glioma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Malignant Glioma - Products under Development by Companies 17 Malignant Glioma - Products under Investigation by Universities/Institutes 18 Malignant Glioma - Companies Involved in Therapeutics Development 19 Advantagene, Inc. 19 Eli Lilly and Company 20 iDD biotech SAS 21 Lipopharma Therapeutics SL 22 Merck & Co., Inc. 23 Nuo Therapeutics, Inc. 24 Orbus Therapeutics, Inc. 25 Sanofi 26 Stemline Therapeutics, Inc. 27 ZIOPHARM Oncology, Inc. 28 Malignant Glioma - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 Ad-RTS-IL-12 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ALD-451 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Dendritic Cell Therapy for Malignant Gliomas - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Dendritic Cell Therapy for Oncology - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Dendritic Cell Therapy for Oncology - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Dendritic Cell Therapy for Oncology - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 eflornithine hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 galunisertib - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GliAtak - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 IDD-004 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 LD-224 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 marizomib - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Minerval - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 pembrolizumab - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 SL-701 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Vaccine to Target Survivin for Malignant Glioma - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 voxtalisib - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Malignant Glioma - Recent Pipeline Updates 70 Malignant Glioma - Dormant Projects 84 Malignant Glioma - Discontinued Products 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 87 Disclaimer 87
List of Tables Number of Products under Development for Malignant Glioma, H1 2015 9 Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Malignant Glioma - Pipeline by Advantagene, Inc., H1 2015 19 Malignant Glioma - Pipeline by Eli Lilly and Company, H1 2015 20 Malignant Glioma - Pipeline by iDD biotech SAS, H1 2015 21 Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H1 2015 22 Malignant Glioma - Pipeline by Merck & Co., Inc., H1 2015 23 Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H1 2015 24 Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H1 2015 25 Malignant Glioma - Pipeline by Sanofi, H1 2015 26 Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015 27 Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Mechanism of Action, H1 2015 33 Number of Products by Stage and Route of Administration, H1 2015 35 Number of Products by Stage and Molecule Type, H1 2015 37 Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015 70 Malignant Glioma - Dormant Projects, H1 2015 84 Malignant Glioma - Discontinued Products, H1 2015 85
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
